| NCT ID | NCT03995121 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Schizophrenia and Other Psychotic Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2017-12-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2017-12-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Eligibility Criteria
Inclusion Criteria: * Willing and able to give voluntary written informed consent * Male and Female subjects, age 18 to 65 years, inclusive Exclusion Criteria: * MRI metal exclusions and claustrophobia. * Education completed is less than 12 years
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03995121 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Schizophrenia and Other Psychotic Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03995121 currently recruiting?
Yes, NCT03995121 is actively recruiting participants. Contact the research team at angerlyk.frytz@yale.edu for enrollment information.
Where is the NCT03995121 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT03995121 clinical trial?
NCT03995121 is sponsored by Yale University. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.